Aliberto, the dual tactical mistake of 1) selling stock under $5.00 and then 2) seeking shelf approval for 5 million new shares stung investors and funds holding shares. Maybe the stock price would have recovered quickly over $5.00 when the entire allotment under $5 was transacted so quickly. But then, Chan and Block in their combined wisdom decided they needed to put another 5 million shares on the shelf. So they made that announcement less than 30 days later. Oh, boy! Poor timing. First, they lowered the market price of the stock, then they asked us for a dilution. It was a double punch to shareholders. I don't think Chan is fully aware that he and Block caused the current share price weakness. He doesn't seem to know that the price point of $5 is magical for some funds -- $10 is another similar point. Some funds can only buy a stock over $5, but if it falls, they must sell their holdings under $5. Chan and Block triggered this selling. So here we languish at the bottom of the chart waiting for the next catalyst to occur. The only relief in sight short term is the end of Q2 in three weeks. BYW, Chan missed the perfect opportunity to provide some relief to shareholders by issuing a statement during the annual meeting last week, updating the German reimbursement switchover. I read on this board that Germany's sales are accelerating anew. Chan could have used this info to reassure investors. But he didn't. Maybe it takes too much effort? Maybe he thinks investors don't care? Summing up, he simply doesn't have a head for the investment community. Honestly, I try not to think about it. The product is so good and fills such an important need (regardless of Pears' snipes) that we should expect global growth to accelerate every quarter, continued reorder pattern strengthening, more 3rd party reimbursement approvals, and new indications to be discovered for a long time to come.
